Osmotica Pharmaceuticals Stock Forecast, Price & News

Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions

Is Osmotica Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Osmotica Pharmaceuticals stock.
View analyst ratings for Osmotica Pharmaceuticals or view top-rated stocks.

Are investors shorting Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 412,200 shares, an increase of 263.5% from the December 15th total of 113,400 shares. Based on an average daily trading volume, of 694,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 1.0% of the shares of the company are short sold.
View Osmotica Pharmaceuticals' Short Interest.

When is Osmotica Pharmaceuticals' next earnings date?

Osmotica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Osmotica Pharmaceuticals.

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.06. The firm had revenue of $2.20 million for the quarter, compared to analyst estimates of $2.39 million. Osmotica Pharmaceuticals had a negative trailing twelve-month return on equity of 81.23% and a negative net margin of 138.76%. During the same quarter in the prior year, the business earned ($0.14) earnings per share.
View Osmotica Pharmaceuticals' earnings history.

What price target have analysts set for OSMT?

5 equities research analysts have issued twelve-month target prices for Osmotica Pharmaceuticals' stock. Their forecasts range from $5.00 to $8.00. On average, they expect Osmotica Pharmaceuticals' share price to reach $6.00 in the next year.
View analysts' price targets for Osmotica Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Osmotica Pharmaceuticals' key executives?

Osmotica Pharmaceuticals' management team includes the following people:

• Brian A. Markison, Chairman & Chief Executive Officer
• James Schaub, Chief Operating Officer & Executive Vice President
• Andrew J. Einhorn, Chief Financial Officer
• Tina Devries, Executive VP-Research & Development
• Sergio Alegre, Vice President-Global Compliance

Who are some of Osmotica Pharmaceuticals' key competitors?

Some companies that are related to Osmotica Pharmaceuticals include Pyxis Oncology (PYXS), Selecta Biosciences (SELB), Cogent Biosciences (COGT), Nanobiotix (NBTX), Kamada (KMDA), Provention Bio (PRVB), Verastem (VSTM), ProQR Therapeutics (PRQR), Immuneering (IMRX), Shattuck Labs (STTK), Thorne Healthtech (THRN), Clovis Oncology (CLVS), Enochian Biosciences (ENOB), Connect Biopharma (CNTB) and Aerovate Therapeutics (AVTE).
View all of OSMT's competitors.

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), AbbVie (ABBV), AT&T (T), (CGC), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and (AZN).

When did Osmotica Pharmaceuticals IPO?

(OSMT) raised $58 million in an IPO on Thursday, October 18th 2018. The company issued 8,300,000 shares at a price of $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

What is Osmotica Pharmaceuticals' stock symbol?

Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."

How do I buy shares of Osmotica Pharmaceuticals?

Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Osmotica Pharmaceuticals make?

Osmotica Pharmaceuticals has a market capitalization of $0.00 and generates $177.88 million in revenue each year. The company earns $-79.59 million in net income (profit) each year or ($1.59) on an earnings per share basis.

How many employees does Osmotica Pharmaceuticals have?

Osmotica Pharmaceuticals employs 302 workers across the globe.

What is Osmotica Pharmaceuticals' official website?

The official website for Osmotica Pharmaceuticals is www.osmotica.com.

Where are Osmotica Pharmaceuticals' headquarters?

Osmotica Pharmaceuticals is headquartered at 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807.

How can I contact Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at (908) 809-1300 or via email at [email protected].